Symptom screening plus a simple blood test improves early detection of ovarian cancerJune 23, 2008SEATTLE - Women's reports of persistent, recent-onset symptoms linked to ovarian cancer - abdominal or pelvic pain, difficulty eating or feeling full quickly and abdominal bloating - when combined with the CA125 blood test may improve the early detection of ovarian cancer by 20 percent, according to new findings by researchers at Fred Hutchinson Cancer Research Center published online today in CANCER. Research has found that when used alone, a simple four-question symptom-screening questionnaire and the CA125 ovarian-cancer blood test each detect about 60 percent of women with early-stage ovarian cancer and 80 percent of those with late-stage disease. This study found that when used together, the questionnaire and blood test may boost early-detection rates to more than 80 percent and late-stage detection rates to more than 95 percent. "Of course, it is the increase in the detection of early-stage disease that is the most exciting," said lead author M. Robyn Andersen, Ph.D., an associate member of the Public Health Sciences Division at the Hutchinson Center. Cure rates for those diagnosed when the disease is confined to the ovary are approximately 70 percent to 90 percent. However, more than 70 percent of women with ovarian cancer are diagnosed with advanced-stage disease, when the survival rate is only 20 percent to 30 percent.
"This research suggests that if a woman has one or more symptoms that are new for her, having begun within the past year, and if the symptoms happen nearly daily or at least 12 times a month, that may well be a signal to go in and discuss those symptoms with her doctor," Andersen said. "It's probably not going to be ovarian cancer, just as most breast lumps are not breast cancer, but it's still a sign that it might be worth checking with her doctor to see if a CA125 blood test and transvaginal ultrasound may be appropriate." Assessing the symptoms included in the symptom-screening index may already be done by some doctors based on a consensus statement issued last year by the National Institutes of Health. The researchers hope their symptom index will help doctors know which among their patients who complain of symptoms such as abdominal swelling and pelvic pain might have cancer. The symptom-screening index, developed in 2006 by paper co-author Barbara A. Goff, M.D., professor and director of Gynecologic Oncology at the University of Washington School of Medicine, is not used proactively in clinical general practice, but Andersen and colleagues are conducting a pilot study to assess the value of using it as a screening tool among normal-risk women as part of their routine medical-history assessment. Fred Hutchinson Cancer Research Center | |||||||||||||||||||||
|
Related Ovarian Cancer News Articles New method to overcome multiple drug resistant diseases developed by Stanford researchers Many drugs once considered Charles Atlases of the pharmaceutical realm have been reduced to the therapeutic equivalent of 97-pound weaklings as the diseases they once dispatched with ease have developed resistance to them. How chemo kills tumours: research to reduce side effects Dr Stephen Taylor and Karen Gascoigne at the University's Faculty of Life Sciences have taken a new systematic approach to studying anti-mitotic drugs, which are used extensively for breast or ovarian cancer in the UK. American Cancer Society study finds high use of complementary methods among cancer survivors A new study from researchers at the American Cancer Society finds many cancer patients use complementary and alternative methods, most often prayer, relaxation, supplements, meditation, and massage. Study finds that significant proportion of men told wife's cancer was incurable late or not at all A study conducted in Sweden found that more than 40 percent of widowers in that country whose wives died from cancer four or five years earlier reported they were either never told that their spouse's cancer was incurable, or they heard this information during the last week of her life. PET/CT scan could be valuable noninvasive tool for determining stages of ovarian cancer Combined positron emission tomography (PET) and computed tomography (CT) scanning of patients in the early stages of ovarian cancer can enable physicians to determine whether the cancer has spread to nearby lymph nodes without having to perform surgery. Glypican-3 gene function in regulating body size helps inform novel cancer treatments In a leading study that has implications for the development of novel therapies for a number of breast, lung and ovarian cancers that have lost the expression of a gene called glypican-3 (GPC3), Sunnybrook researchers have discovered how the loss of the GPC3 gene induces overgrowth through certain growth factors such as Sonic Hedgehog which stimulate cancer growth. Researchers identify new cell targets for preventing growth of breast and other tumors Researchers at the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have discovered new targets for cancer treatment aimed at blocking a key step in tumor progression. Researchers identify new cell targets for preventing growth of breast and other tumors Researchers at the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have discovered new targets for cancer treatment aimed at blocking a key step in tumor progression. Ovarian cancer stem cells identified, characterized Researchers at Yale School of Medicine have identified, characterized and cloned ovarian cancer stem cells and have shown that these stem cells may be the source of ovarian cancer's recurrence and its resistance to chemotherapy. Drug compound leads to death of ovarian cancer cells resistant to chemotherapy In a discovery that may be useful for maintaining remission in chemo-resistant ovarian cancer, Yale scientists report that pre-clinical studies have shown the drug compound NV-128 can induce the death of ovarian cancer cells by halting the activation of a protein pathway called mTOR. More Ovarian Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||